Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo

IL (interleukin)-8 [CXCL8 (CXC chemokine ligand 8)] exerts its role in inflammation by triggering neutrophils via its specific GPCRs (G-protein-coupled receptors), CXCR1 (CXC chemokine receptor 1) and CXCR2, for which additional binding to endothelial HS-GAGs (heparan sulphate-glycosaminoglycans) is...

Full description

Bibliographic Details
Main Authors: Mauro M. Teixeira, Andreas J. Kungl, Tiziana Adage, Angelika Falsone, Veronica Wabitsch, Elena Geretti, Heide Potzinger, Tanja Gerlza, James Robinson
Format: Article
Language:English
Published: Portland Press, Biochemical Society 2013-09-01
Series:Bioscience Reports
Subjects:
Online Access:http://www.bioscirep.org/bsr/033/e068/bsr033e068.htm
id doaj-1629864bb3a7455eae782d7ce4f3d401
record_format Article
spelling doaj-1629864bb3a7455eae782d7ce4f3d4012020-11-25T00:27:52ZengPortland Press, Biochemical SocietyBioscience Reports0144-84631573-49352013-09-01335e0006810.1042/BSR20130069Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivoMauro M. TeixeiraAndreas J. KunglTiziana AdageAngelika FalsoneVeronica WabitschElena GerettiHeide PotzingerTanja GerlzaJames RobinsonIL (interleukin)-8 [CXCL8 (CXC chemokine ligand 8)] exerts its role in inflammation by triggering neutrophils via its specific GPCRs (G-protein-coupled receptors), CXCR1 (CXC chemokine receptor 1) and CXCR2, for which additional binding to endothelial HS-GAGs (heparan sulphate-glycosaminoglycans) is required. We present here a novel approach for blocking the CXCL8-related inflammatory cascade by generating dominant-negative CXCL8 mutants with improved GAG-binding affinity and knocked-out CXCR1/CXCR2 activity. These non-signalling CXCL8 decoy proteins are able to displace WT (wild-type) CXCL8 and to prevent CXCR1/CXCR2 signalling thereby interfering with the inflammatory response. We have designed 14 CXCL8 mutants that we subdivided into three classes according to number and site of mutations. The decoys were characterized by IFTs (isothermal fluorescence titrations) and SPR (surface plasmon resonance) to determine GAG affinity. Protein stability and structural changes were evaluated by far-UV CD spectroscopy and knocked-out GPCR response was shown by Boyden chamber and Ca2+ release assays. From these experiments, CXCL8(Δ6F17KF21KE70KN71K) emerged with the most promising in vitro characteristics. This mutant was therefore further investigated in a murine model of mBSA (methylated BSA)-induced arthritis in mice where it showed strong anti-inflammatory activity. Based on these results, we propose that dominant-negative CXCL8 decoy proteins are a promising class of novel biopharmaceuticals with high therapeutic potential in inflammatory diseases.http://www.bioscirep.org/bsr/033/e068/bsr033e068.htmanti-inflammatorychemokine decoyscompetitionGAG affinityheparan sulphate
collection DOAJ
language English
format Article
sources DOAJ
author Mauro M. Teixeira
Andreas J. Kungl
Tiziana Adage
Angelika Falsone
Veronica Wabitsch
Elena Geretti
Heide Potzinger
Tanja Gerlza
James Robinson
spellingShingle Mauro M. Teixeira
Andreas J. Kungl
Tiziana Adage
Angelika Falsone
Veronica Wabitsch
Elena Geretti
Heide Potzinger
Tanja Gerlza
James Robinson
Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
Bioscience Reports
anti-inflammatory
chemokine decoys
competition
GAG affinity
heparan sulphate
author_facet Mauro M. Teixeira
Andreas J. Kungl
Tiziana Adage
Angelika Falsone
Veronica Wabitsch
Elena Geretti
Heide Potzinger
Tanja Gerlza
James Robinson
author_sort Mauro M. Teixeira
title Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
title_short Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
title_full Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
title_fullStr Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
title_full_unstemmed Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo
title_sort designing cxcl8-based decoy proteins with strong anti-inflammatory activity in vivo
publisher Portland Press, Biochemical Society
series Bioscience Reports
issn 0144-8463
1573-4935
publishDate 2013-09-01
description IL (interleukin)-8 [CXCL8 (CXC chemokine ligand 8)] exerts its role in inflammation by triggering neutrophils via its specific GPCRs (G-protein-coupled receptors), CXCR1 (CXC chemokine receptor 1) and CXCR2, for which additional binding to endothelial HS-GAGs (heparan sulphate-glycosaminoglycans) is required. We present here a novel approach for blocking the CXCL8-related inflammatory cascade by generating dominant-negative CXCL8 mutants with improved GAG-binding affinity and knocked-out CXCR1/CXCR2 activity. These non-signalling CXCL8 decoy proteins are able to displace WT (wild-type) CXCL8 and to prevent CXCR1/CXCR2 signalling thereby interfering with the inflammatory response. We have designed 14 CXCL8 mutants that we subdivided into three classes according to number and site of mutations. The decoys were characterized by IFTs (isothermal fluorescence titrations) and SPR (surface plasmon resonance) to determine GAG affinity. Protein stability and structural changes were evaluated by far-UV CD spectroscopy and knocked-out GPCR response was shown by Boyden chamber and Ca2+ release assays. From these experiments, CXCL8(Δ6F17KF21KE70KN71K) emerged with the most promising in vitro characteristics. This mutant was therefore further investigated in a murine model of mBSA (methylated BSA)-induced arthritis in mice where it showed strong anti-inflammatory activity. Based on these results, we propose that dominant-negative CXCL8 decoy proteins are a promising class of novel biopharmaceuticals with high therapeutic potential in inflammatory diseases.
topic anti-inflammatory
chemokine decoys
competition
GAG affinity
heparan sulphate
url http://www.bioscirep.org/bsr/033/e068/bsr033e068.htm
work_keys_str_mv AT maurox00a0mteixeira designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT andreasx00a0jkungl designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT tizianaadage designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT angelikafalsone designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT veronicawabitsch designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT elenageretti designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT heidepotzinger designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT tanjagerlza designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
AT jamesrobinson designingcxcl8baseddecoyproteinswithstrongantiinflammatoryactivityinx00a0vivo
_version_ 1725338061003292672